Respiratory Infections

A 2-year retrospective study looking at patients admitted to the ICU showed that the number of intubated males infected with Acinetobacter baumannii (AB) was double the number of intubated females.

The agency licensed the new indication for Sanofi’s Adacel (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed [Tdap]) shot for immunization during the third trimester of pregnancy.

RSV cases spiked to unprecedented levels this season. Why were these infections so frequent and severe? Why has vaccine development taken so long?

Newer diagnostic technologies can play a role in identifying specific bacterium, decrease the time to optimal therapy, and offer the possibility of better outcomes.

So far, these are Contagion's 5 most-read stories of 2023.

Developed by Sanofi and AstraZeneca, the single-dose long-acting antibody was designed to help protect all infants from birth through their first respiratory syncytial virus (RSV) season.

The 24-valent investigational pneumococcal conjugate vaccine, VAX-24, met its primary endpoints in a phase 1/2 trial.

Due to negative results, the I-SPY COVID Trial is no longer evaluating cyproheptadine to treat critically ill COVID-19 patients.

During the COVID-19 pandemic, cigarette sales differed from projected sales volume. One study examined these trends at the state level.

Editor-in-Chief Jason Gallagher discusses the surging number of cases of influenza and RSV while there is a concomitant shortage of amoxicillin suspension.

With these findings, the Uppsala University investigators believe loss of the Y chromosome in white blood cells can predict which patients are at high risk of severe COVID-19 disease progression.

All regions are experiencing influenza-like illness levels above the baseline, the CDC said.

Priorix and M-M-R II are fully interchangeable vaccines to protect against measles, mumps, and rubella, the CDC’s Advisory Committee on Immunization Practices said.

Earlier and higher rates of RSV and other respiratory illnesses following reduced COVID precautions challenge capacity of pediatric units.

An ICU hospitalist talks about his criteria and the treatment protocols for these cases.

Dynavax reported results from its phase 1 study looking at its (Tdap-1018 CpG Adjuvanted) Tetanus/Diphtheria/Pertussis booster vaccine.

The benefits to children of wearing face masks to prevent COVID-19 outweigh potential infectious risks from face touching, according to a study analyzing hand-to-face contact in a simulated school environment.

The intranasal, live-attenuated vaccine CodaVax-RSV was granted FDA Fast Track designation. Clinical trials are expected to launch soon.

Vaccine efficacy of 81.8% was observed against severe medically attended lower respiratory tract illness due to respiratory syncytial virus (RSV) in infants from birth through the first 90 days of life.

Our cover story for the October 2022 print edition of Contagion details the original coronavirus.

The investigational vaccine was effective in reducing both lower respiratory tract and all respiratory tract infections.

Despite no significant reduction in time to discharge or recovery, inhalable SNG001 may lessen common symptoms of “long COVID.”

Ahead of the IDWeek 2022 conference, GSK shared data from their phase 3 RSV vaccine trial.

Before the emergence of COVID-19, this precursor virus was a global concern.

Articles covering respiratory infections were our most-clicked this week.